BGPT: Best Evidence: Extract Only Clinical Efficacy Endpoints from NCT ids in 10.32604/or.2025.066624

Explore by Goal

Quick Explanation Copied

Evidence-extraction block

I can’t extract “clinical efficacy endpoints from NCT ids in 10.32604/or.2025.066624” from the material currently provided to me, because the prompt does not include the actual NCT IDs, the trial records, or the relevant endpoint tables/results text.

Long Explanation

What you asked vs. what is extractable right now

Task: “Extract Only Clinical Efficacy Endpoints from NCT ids in 10.32604/or.2025.066624.”

Required inputs: the paper’s linked NCT IDs (or the NCT registry links/text) and the endpoint definitions + efficacy results for each NCT record.

Current status: the conversation includes no NCT identifiers or trial endpoint/result tables corresponding to the DOI you specified, so no faithful endpoint extraction can be performed without guessing.

Critical battle-test (epistemic check)

Selection bias risk: without the NCT IDs, I could accidentally extract endpoints from unrelated trials.
Endpoint misclassification risk: “clinical efficacy” must be distinguished from safety/surrogate/procedural endpoints; without the endpoint taxonomy as written in the NCT records, mislabeling is easy.
Selective reporting risk: endpoint reporting differs between protocols, registry entries, and publications; without full NCT fields, I can’t verify which endpoints were pre-specified.
Reproducibility risk: endpoint extraction should be traceable to specific NCT fields (e.g., primary outcome measures, secondary outcome measures, timepoints).

Minimal information I need from you (pick one)

Option A (best): paste the NCT IDs listed by 10.32604/or.2025.066624 (even just the NCT numbers).

Option B: paste the NCT registry “Outcomes” text for each NCT ID (primary + secondary outcomes, timepoints).

Option C: paste the relevant excerpt(s) from the paper where it enumerates NCT-linked trial endpoints.

If you want, I can run an iterative extraction agent

The agent will (1) retrieve the NCT IDs for 10.32604/or.2025.066624, (2) extract only clinical efficacy endpoints from each NCT record, and (3) output a traceable table keyed by NCT ID + endpoint + timepoint + measure.

Note: The research snippets included in your message are not the trial/registry content for DOI 10.32604/or.2025.066624, so they can’t support endpoint extraction for your requested NCT-linked evidence.

Feedback:

Updated: April 11, 2026

Top Data Sources Export MCP

1. A systematic, quantitative analysis of cardiovascular device clinical trials published in high-impact journals from 2001 to 2012, detailing trends in trial size, international expansion, funding, end points, and enrollment patterns. [2015]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This paper summarizes recommendations from a National Institutes of Health workshop on evaluating surrogate endpoints in clinical trials, emphasizing the need for collaboration between biostatisticians and laboratory scientists to improve the use of biomarkers in clinical research. [2001]

8QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

3. This study proposes a flexible fixed-sequence testing method that accounts for correlations among multiple endpoints in clinical trials, enhancing power while controlling the family-wise type I error rate. [2008]

8QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

4. This study critiques the use of composite endpoints in heart failure clinical trials, proposing the probability index as a more informative measure of treatment effect and heterogeneity across outcomes. [2017]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. This study investigates how the sensitivity and specificity of measurement instruments affect the power of randomized clinical trials to detect differences in secondary endpoints, specifically focusing on post-traumatic stress symptoms in patients with Acute Respiratory Distress Syndrome (ARDS). [2017]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

Clinical-efficacy endpoint extraction is only as trustworthy as the traceability chain (paper → NCT ID → outcomes fields); missing the NCT IDs collapses the evidence chain and turns extraction into speculation—so the first scientific move is to restore provenance, not to summarize outcomes.

Keep Exploring

Which NCT endpoints are explicitly labeled as clinical efficacy (primary/secondary) versus safety/biomarker/procedural, and what exact timepoints are used?

Do the registry-defined primary outcomes match the paper’s efficacy analyses, and if not, what changed (endpoint name/timepoint/population)?

Across the extracted clinical-efficacy endpoints, what is the distribution of endpoint types (e.g., survival, symptom scales, response rates) and how might that affect comparability?

Analysis Wizard

It will first retrieve the NCT IDs linked to DOI 10.32604/or.2025.066624, then scrape each NCT outcomes section and export a clean table containing only clinical-efficacy endpoints and timepoints.

Hypothesis Graveyard

A common failure mode is assuming that every NCT “Outcome Measure” labeled as an “endpoint” is clinical efficacy; this is unlikely—registries often include safety, biomarkers, and composite constructs without clear clinical-efficacy intent.

Another failure mode is assuming that “primary outcome” in the paper matches “primary outcome” in the registry; this is unlikely—trial outcomes can be amended, and registry entries may lag publications.

Potential Experiments

Collect NCT IDs from the DOI’s trial citations, then build a rule-based extraction schema that tags each endpoint as clinical efficacy vs safety vs biomarker strictly from NCT field wording; measure agreement by dual-pass extraction and report disagreements.

For each extracted efficacy endpoint, extract all timepoint labels and compute a “timepoint alignment score” across NCTs; test whether downstream synthesis conclusions change when enforcing identical/nearest-neighbor timepoints rather than loosely aligning by “around 12 weeks”.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I default to provenance-first skepticism: without NCT IDs/endpoints text, I avoid performing extraction that would be guesswork.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Top Data Sources Export MCP

1. A systematic, quantitative analysis of cardiovascular device clinical trials published in high-impact journals from 2001 to 2012, detailing trends in trial size, international expansion, funding, end points, and enrollment patterns. [2015]

2. This paper summarizes recommendations from a National Institutes of Health workshop on evaluating surrogate endpoints in clinical trials, emphasizing the need for collaboration between biostatisticians and laboratory scientists to improve the use of biomarkers in clinical research. [2001]

3. This study proposes a flexible fixed-sequence testing method that accounts for correlations among multiple endpoints in clinical trials, enhancing power while controlling the family-wise type I error rate. [2008]

4. This study critiques the use of composite endpoints in heart failure clinical trials, proposing the probability index as a more informative measure of treatment effect and heterogeneity across outcomes. [2017]

6. This paper discusses the design and endpoints of clinical trials in hepatocellular carcinoma (HCC), highlighting the challenges faced in standardizing trial methodologies and endpoints to improve patient outcomes. [2008]

7. This EAACI Position Paper provides recommendations for standardizing clinical outcomes in allergen immunotherapy trials for allergic rhinoconjunctivitis, emphasizing the need for a combined symptom and medication score as the primary endpoint. [2014]

11. This paper discusses the application of surrogate endpoints in clinical trials, particularly focusing on the relationship between bone mineral density and osteoporotic fractures, and emphasizes the need for strong evidence linking surrogate outcomes to clinically meaningful endpoints. [1999]

12. This study presents a Bayesian-decision theoretic approach to determine the appropriate sample size for clinical trials with binary endpoints, comparing it to traditional Neyman-Pearson methods and providing a program for practical implementation. [2001]

Ask a Follow-Up

Key Insight

Clinical-efficacy endpoint extraction is only as trustworthy as the traceability chain (paper → NCT ID → outcomes fields); missing the NCT IDs collapses the evidence chain and turns extraction into speculation—so the first scientific move is to restore provenance, not to summarize outcomes.

Keep Exploring

Which NCT endpoints are explicitly labeled as clinical efficacy (primary/secondary) versus safety/biomarker/procedural, and what exact timepoints are used?

Do the registry-defined primary outcomes match the paper’s efficacy analyses, and if not, what changed (endpoint name/timepoint/population)?

Across the extracted clinical-efficacy endpoints, what is the distribution of endpoint types (e.g., survival, symptom scales, response rates) and how might that affect comparability?

Analysis Wizard

It will first retrieve the NCT IDs linked to DOI 10.32604/or.2025.066624, then scrape each NCT outcomes section and export a clean table containing only clinical-efficacy endpoints and timepoints.

Hypothesis Graveyard

A common failure mode is assuming that every NCT “Outcome Measure” labeled as an “endpoint” is clinical efficacy; this is unlikely—registries often include safety, biomarkers, and composite constructs without clear clinical-efficacy intent.

Another failure mode is assuming that “primary outcome” in the paper matches “primary outcome” in the registry; this is unlikely—trial outcomes can be amended, and registry entries may lag publications.

Potential Experiments

Collect NCT IDs from the DOI’s trial citations, then build a rule-based extraction schema that tags each endpoint as clinical efficacy vs safety vs biomarker strictly from NCT field wording; measure agreement by dual-pass extraction and report disagreements.

For each extracted efficacy endpoint, extract all timepoint labels and compute a “timepoint alignment score” across NCTs; test whether downstream synthesis conclusions change when enforcing identical/nearest-neighbor timepoints rather than loosely aligning by “around 12 weeks”.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I default to provenance-first skepticism: without NCT IDs/endpoints text, I avoid performing extraction that would be guesswork.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Top Data Sources ExportMCP

1. A systematic, quantitative analysis of cardiovascular device clinical trials published in high-impact journals from 2001 to 2012, detailing trends in trial size, international expansion, funding, end points, and enrollment patterns. [2015]

2. This paper summarizes recommendations from a National Institutes of Health workshop on evaluating surrogate endpoints in clinical trials, emphasizing the need for collaboration between biostatisticians and laboratory scientists to improve the use of biomarkers in clinical research. [2001]

3. This study proposes a flexible fixed-sequence testing method that accounts for correlations among multiple endpoints in clinical trials, enhancing power while controlling the family-wise type I error rate. [2008]

4. This study critiques the use of composite endpoints in heart failure clinical trials, proposing the probability index as a more informative measure of treatment effect and heterogeneity across outcomes. [2017]

6. This paper discusses the design and endpoints of clinical trials in hepatocellular carcinoma (HCC), highlighting the challenges faced in standardizing trial methodologies and endpoints to improve patient outcomes. [2008]

7. This EAACI Position Paper provides recommendations for standardizing clinical outcomes in allergen immunotherapy trials for allergic rhinoconjunctivitis, emphasizing the need for a combined symptom and medication score as the primary endpoint. [2014]

11. This paper discusses the application of surrogate endpoints in clinical trials, particularly focusing on the relationship between bone mineral density and osteoporotic fractures, and emphasizes the need for strong evidence linking surrogate outcomes to clinically meaningful endpoints. [1999]

12. This study presents a Bayesian-decision theoretic approach to determine the appropriate sample size for clinical trials with binary endpoints, comparing it to traditional Neyman-Pearson methods and providing a program for practical implementation. [2001]

Ask a Follow-Up

Key Insight

Clinical-efficacy endpoint extraction is only as trustworthy as the traceability chain (paper → NCT ID → outcomes fields); missing the NCT IDs collapses the evidence chain and turns extraction into speculation—so the first scientific move is to restore provenance, not to summarize outcomes.

Keep Exploring

Which NCT endpoints are explicitly labeled as clinical efficacy (primary/secondary) versus safety/biomarker/procedural, and what exact timepoints are used?

Do the registry-defined primary outcomes match the paper’s efficacy analyses, and if not, what changed (endpoint name/timepoint/population)?

Across the extracted clinical-efficacy endpoints, what is the distribution of endpoint types (e.g., survival, symptom scales, response rates) and how might that affect comparability?

Analysis Wizard

It will first retrieve the NCT IDs linked to DOI 10.32604/or.2025.066624, then scrape each NCT outcomes section and export a clean table containing only clinical-efficacy endpoints and timepoints.

Hypothesis Graveyard

A common failure mode is assuming that every NCT “Outcome Measure” labeled as an “endpoint” is clinical efficacy; this is unlikely—registries often include safety, biomarkers, and composite constructs without clear clinical-efficacy intent.

Another failure mode is assuming that “primary outcome” in the paper matches “primary outcome” in the registry; this is unlikely—trial outcomes can be amended, and registry entries may lag publications.

Potential Experiments

Collect NCT IDs from the DOI’s trial citations, then build a rule-based extraction schema that tags each endpoint as clinical efficacy vs safety vs biomarker strictly from NCT field wording; measure agreement by dual-pass extraction and report disagreements.

For each extracted efficacy endpoint, extract all timepoint labels and compute a “timepoint alignment score” across NCTs; test whether downstream synthesis conclusions change when enforcing identical/nearest-neighbor timepoints rather than loosely aligning by “around 12 weeks”.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I default to provenance-first skepticism: without NCT IDs/endpoints text, I avoid performing extraction that would be guesswork.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP